Every 10-Q that Ocugen, Inc. (OCGN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OCGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OCGN filings page.
Ocugen, Inc., a gene therapy biotechnology company, reported continued operating losses and significant financing activity for the quarter ended June 30, 2026. Collaborative arrangement revenue was modest at $1.5 million for the quarter and $3.0 million for the first half of 2026, while research and development and general and administrative expenses drove a quarterly net loss of $24.9 million and a year-to-date net loss of $44.1 million.
Cash and cash equivalents increased to $100.1 million from $18.6 million at year-end, primarily due to a January underwritten offering, warrant exercises, and a May private offering of $130.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034. About $32.7 million of the note proceeds were used to fully repay and terminate a prior term loan; the remainder is for general corporate purposes. The new convertible notes, together with an associated $33.7 million derivative liability, are classified as current liabilities pending shareholder approval to increase authorized shares.
Despite the strengthened cash position, Ocugen has an accumulated deficit of $452.1 million, negative stockholders’ equity of $16.6 million, and used $34.0 million of cash in operating activities in the first half of 2026. Management concluded there is substantial doubt about the company’s ability to continue as a going concern within one year after the financial statements’ issuance and is evaluating additional capital raises, spending adjustments, and strategic options.
Ocugen, Inc. reported a larger net loss of $19.2 million for the quarter ended March 31, 2026, compared with $15.4 million a year earlier, driven by higher research and development and general and administrative expenses. Collaborative arrangement revenue was stable at $1.5 million, but operating expenses rose to $19.4 million, reflecting advancement of its gene therapy pipeline. Cash was $31.9 million and total assets $56.9 million, against total liabilities of $51.1 million. The company states that existing cash will not fund operations for 12 months after issuance of these financial statements and explicitly discloses substantial doubt about its ability to continue as a going concern, despite recent equity and warrant financings. After quarter‑end, Ocugen issued $115.0 million of 6.75% Convertible Senior Notes due 2034 and used $32.7 million of the proceeds to repay its Avenue Capital term loan.
Ocugen, Inc. filed its Q3 2025 10-Q, reporting collaborative revenue of $1.75 million and a net loss of $20.05 million (basic/diluted loss per share $0.07). Operating expenses were $19.38 million, driven by R&D of $11.15 million and G&A of $8.23 million. Interest expense rose to $1.31 million in the quarter.
Cash was $32.57 million and total assets $57.60 million at September 30, 2025. Total liabilities were $54.06 million, leaving stockholders’ equity at $3.53 million. Management disclosed substantial doubt about the company’s ability to continue as a going concern within one year due to expected funding needs. Cash used in operations for the nine months was $43.00 million.
Financing included an August 2025 registered direct offering of 20,000,000 shares plus 20,000,000 warrants for $18.5 million net, and the November 2024 Avenue loan with $30.0 million principal outstanding. The NeoCart merger agreement with Carisma was terminated on September 16, 2025. Common shares outstanding were 312,320,112 as of October 31, 2025.